<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02382432</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00008718</org_study_id>
    <nct_id>NCT02382432</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine in Post Spinal Anesthesia Shivering</brief_title>
  <official_title>Safety and Efficacy of Dexmedetomidine in Treating Post Spinal Anesthesia Shivering: A Clinically Controlled Dose-finding Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluated the effect of dexmedetomidine iv in three different doses in the
      treatment of shivering in patients undergoing minor elective abdominal surgery under spinal
      anesthesia, in comparison with intravenous pethidine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Among the pharmacological agents used in treatment of shivering, pethidine (meperidine) has
      been shown to be one of the most effective treatments.The α-2 receptor agonists are another
      important class of anti-shivering drugs that, unlike meperidine, produce little respiratory
      depression.

      Dexmedetomidine is a highly selective α-2 adrenoceptor agonist with potent effects on the
      central nervous system . Intravenous dexmedetomidine reduces both the vasoconstriction and
      shivering thresholds . Clinical studies had demonstrated the efficacy of dexmedetomidine in
      prevention of shivering . Few clinical trials investigated its efficacy in treatment of
      established shivering. The optimum dose for shivering control with the least hemodynamic
      derangements is still under research.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Shivering response rate (%)</measure>
    <time_frame>10 minutes</time_frame>
    <description>complete cessation of shivering activity within 10 minutes after study drug injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>6 hours after study drug injection</time_frame>
    <description>find for systolic hypotension, hypertension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sedation</measure>
    <time_frame>6 hours after study drug injection</time_frame>
    <description>using an Observer's Assessment of Alertness/Sedation Scale (OAA/SS) (where 5 = Responds readily to name spoken in normal tone, 4 = Lethargic response to name spoken in normal tone, 3 = Responds only after name is spoken loudly and/or repeatedly, 2 = Responds only after mild prodding or shaking, 1 = Does not respond to mild prodding or shaking).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peripheral arterial saturation</measure>
    <time_frame>6 hours after study drug injection</time_frame>
    <description>find for hypoxia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diastolic blood pressure</measure>
    <time_frame>6 hours after study drug injection</time_frame>
    <description>find for diastolic hypertension or hypotension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative adverse events</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>postoperative nausea and vomiting, urine retention, post dural puncture headache ect.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>heart rate</measure>
    <time_frame>6 hours after study drug injection</time_frame>
    <description>find for bradycardia or tachycardia</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Shivering Caused by Spinal Anesthesia</condition>
  <arm_group>
    <arm_group_label>Pethidine 0.4mg/kg iv</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>interventional: Pethidine 0.4mg/kg intravenous bolus once to be repeated if shivering incompletely abolished.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DEX. I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interventional:Dexmedetomidine (Precedex) 0.5µg/kg intravenous bolus once to be repeated if shivering incompletely abolished.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DEX. II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interventional: Dexmedetomidine (PRECEDEX) 0.3µg/kg intravenous bolus given once to be repeated if shivering incompletely abolished.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DEX III</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interventional: Dexmedetomidine (PRECEDEX) 0.2µg/kg intravenous bolus given once to be repeated if shivering incompletely abolished.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pethidine 0.4mg/kg</intervention_name>
    <description>2ml intravenous bolus slowly injected in 2minutes.</description>
    <arm_group_label>Pethidine 0.4mg/kg iv</arm_group_label>
    <other_name>Meperidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>2ml intravenous bolus slowly injected in 2minutes</description>
    <arm_group_label>DEX. I</arm_group_label>
    <arm_group_label>DEX. II</arm_group_label>
    <arm_group_label>DEX III</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologist class I or II scheduled for elective minor lower
             abdominal operations under spinal anesthesia for an anticipated duration of &gt;60 and
             &lt;180 min. (e.g. inguinal herniorRaphy, umbilical hernia repair) who developed
             shivering during the intra or postoperative period

        Exclusion Criteria:

          -  Patients with BMI&gt;30 kg /m2

          -  Initial body temperature &gt;38 C or &lt;36 C and those with a history of convulsions

          -  Multiple allergies

          -  Thyroid disease

          -  Parkinson's disease

          -  Dysautonomia

          -  Raynaud's syndrome

          -  Hypertension

          -  Coronary artery disease or other cardio-respiratory or neuromuscular pathology

          -  Middle ear pathology

          -  A known history of alcohol use

          -  Treatment with sedative hypnotic agents or vasodilators

          -  Having contraindications to spinal anesthesia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hala S Abdel-Ghaffar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>assistant professor in anesthesia, faculty of medicine, Assiut university, Assiut, Egypt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assiut university hospital, Assiut, Egypt</name>
      <address>
        <city>Assiut</city>
        <state>Assiut governorate</state>
        <zip>715715</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2015</study_first_submitted>
  <study_first_submitted_qc>March 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2015</study_first_posted>
  <last_update_submitted>March 3, 2015</last_update_submitted>
  <last_update_submitted_qc>March 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Hala Saad Abdel-Ghaffar</investigator_full_name>
    <investigator_title>Assistant professor in anesthesia department, faculty of medicine, Assiut university</investigator_title>
  </responsible_party>
  <keyword>Anesthesia</keyword>
  <keyword>dexmedetomidine</keyword>
  <keyword>pethidine</keyword>
  <keyword>shivering</keyword>
  <keyword>spinal</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Meperidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

